INFARMA has elected a new president and board. He talks about the challenges facing the industry

• Wiktor Janicki has been involved in the pharmaceutical industry for 20 years.
• As the newly elected president of INFARMA, he takes over at an important moment for the industry, during consultations on the amendment to the Reimbursement Act.
• - As an industry, we want to make Europe a place for research, development and production of new diagnostic methods, therapies and vaccines again - indicates the new president

During the last General Meeting of the Employers’ Association of Innovative Pharmaceutical Companies INFARMA (12 June), a new composition of the Management Board and Supervisory Board was elected for the next 3-year term.

Wiktor Janicki, CEO of AstraZeneca Pharma Poland, will serve as president of INFARMA.

Janicki has been involved in the pharmaceutical industry for 20 years. He joined the sector in 2003 as a financial analyst and held increasingly responsible positions until he became the CFO of Wyeth in the Czech Republic and Slovakia.

In 2010, he returned to Poland and joined Roche as Financial Director, and then in 2015 he took up the position of CEO of Roche Polska.

In May 2021, he joined AstraZeneca Pharma Poland, taking on the role of CEO. One of his goals is for the innovative pharmaceutical industry to play an active, important role in raising healthcare standards in Poland.

As the newly elected President of INFARMA, he takes the helm at an important moment for the industry, during public consultations on the amendment to the Reimbursement Act and the final stage of the EU legislative process for the first reform of EU pharmaceutical law in 20 years, which will impact Europe’s competitiveness and the future of the innovative pharmaceutical industry.

- This is a great honor and proof of trust for me (...) As an industry, we want to make Europe a place of research, development and production of new diagnostic methods, therapies and vaccines again. And we are constantly working on it. I am therefore extremely happy about our joint work, deeply believing that it is the innovative industry that plays a key role in the public debate, shaping a strong and stable healthcare sector in our country and in Europe, really influencing the improvement of access of Polish patients to the latest therapies and, consequently, their health, quality of life and safety - says Wiktor Janicki, President of the Management Board of INFARMA.

Janicki also thanked Phil Krzyzek, as the outgoing president, for his commitment and significant contribution to building dialogue within the Polish presidency, whose legislative and health priorities contributed to increasing the role of education and awareness of the value of prevention, digitization and the mental health of children and youth.

Phil Krzyzek, as Managing Director at Merck Sp. z o. o., took over the position of President of INFARMA in December 2024 and held it until the end of the 3rd term of office of the Management Board in June this year during the Polish Presidency of the EU Council.

- Serving as the president of INFARMA for the past few months has been a great honor for me. In a period of many new geopolitical challenges, the Polish presidency of the EU Council has gained even more significance thanks to the precise definition of priorities and raising health to the rank of one of the 7 pillars of security - emphasizes Phil Krzyzek.

- I believe that thanks to this, further dialogue on health security will take place in an atmosphere of understanding that health is an investment in the health condition of societies, the effectiveness of health care systems and the development of the economy. I am convinced that our industry will continue to be an important partner in the process of building a competitive Europe that ensures health security - he adds.

Delegates during the General Assembly also elected members of the board and the Supervisory Board of the Employers' Association of Innovative Pharmaceutical Companies INFARMA. The board included:

• Wiktor Janicki, Astra Zeneca Poland Sp. z o. o. - President of the Management Board
• Cristiano Costanzo, GSK Commercial Sp. z o. o. - Vice President of the Management Board
• Piotr Debski, Biogen Poland Sp. z o. o. - Treasurer
• Krisztián Szabolcs Toka, Amgen Sp. z o. o
• Pia Schall, Boehringer Ingelheim Sp. z o. o
• Antoni Żarski, BMS Polska Sp. z o. o.
• Geraldine Schenk-Moestl, Janssen-Cilag Polska Sp. z o. o
• Justin Gandy, MSD Polska Sp. z o. o.
• Michaela Scheiffert, Sanofi Sp. z o. o

The Supervisory Board consists of:

• Aleksander Kwiecinski, AbbVie Polska Sp. z o.o.
• Charlampos Nardis, Astellas Pharma Poland Sp. z o. o
• Magdalena Paradzińska, Novo Nordisk Pharma Sp. z o. o.
• Tomasz Stasiewski, UCB Pharma Sp. z o. o.

Copyrighted material - reprint rules are specified in the regulations .